nach oben

Rheumatology International

Erschienen in:

01.09.2007 | Original Article

Activin A suppresses interleukin-1-induced matrix metalloproteinase 3 secretion in human chondrosarcoma cells

verfasst von: Deh-Ming Chang, Shao-Hsiang Liu, Herng-Sheng Lee, Jenn-Hung Lai, Chen-Hung Chen

Erschienen in: Rheumatology International | Ausgabe 11/2007

Einloggen, um Zugang zu erhalten

Abstract

The objective was to investigate the effect of activin A on matrix metalloproteinase 3 (MMP-3) production and to identify the role of activin A in chondroprotection. SW1353 cells, a human chondrosarcoma cell line, were stimulated with interleukin (IL) 1α and tumor necrosis factor (TNF) α, and the concentrations of activin A, follistatin, and MMP-3 secreted into the culture media were measured by enzyme-linked immunosorbent assay (ELISA). Activin A was added to cell cultures in the presence of IL-1α or TNFα to determine its effect on the production of MMP-3 and sulfated glycosaminoglycan (sGAG) (measured by Alcian blue assay). To study the mechanism responsible for the chondroprotective effects of activin A, the production of IL-1 receptor antagonist (IL-1ra) and tissue inhibitor for metalloproteinases 1 (TIMP-1) was examined by ELISA. Addition of IL-1α did not affect the production of activin A by cultured SW1353 cells. IL-1α and activin A inhibited the production of follistatin. Stimulation of SW1353 cells with activin A suppressed IL-1α-induced, but not TNFα-induced, MMP-3 expression. Activin A had no effect on the production of sGAG, IL-1ra, or TIMP-1, although it suppressed the induction of TIMP-1 and IL-1ra by IL-1α. This novel finding of MMP-3 inhibition by activin A suggests a new role of activin A in cartilage remodeling. Activin A may have therapeutic potential for preventing cartilage degradation.

Miyazono K, Kusanagi K, Inoue H (2001) Divergence and convergence of TGF-beta/BMP signaling. J Cell Physiol 187(3):265–76PubMedCrossRef

Neumann E, Judex M, Kullmann F, Grifka J, Robbins PD, Pap T et al (2002) Inhibition of cartilage destruction by double gene transfer of IL-1Ra and IL-10 involves the activin pathway. Gene Ther 9(22):1508–1519PubMedCrossRef

Mathews LS, Vale WW (1993) Characterization of type II activin receptors. Binding, processing, and phosphorylation. J Biol Chem 268(25):19013–19018PubMed

Mathews LS, Vale WW (1993) Molecular and functional characterization of activin receptors. Receptor 3(3):173–181PubMed

Ling N, Ying SY, Ueno N, Shimasaki S, Esch F, Hotta M et al (1986) Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin. Nature 321(6072):779–782PubMedCrossRef

Woodruff TK (1998) Regulation of cellular and system function by activin. Biochem Pharmacol 55(7):953–963PubMedCrossRef

Chen YG, Lui HM, Lin SL, Lee JM, Ying SY (2002) Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med Maywood 227(2):75–87PubMed

Gribi R, Tanaka T, Harper-Summers R, Yu J (2001) Expression of activin A in inflammatory arthropathies. Mol Cell Endocrinol 180(1–2):163–167PubMedCrossRef

Phillips DJ, Jones KL, Scheerlinck JY, Hedger MP, de Kretser DM (2001) Evidence for activin A and follistatin involvement in the systemic inflammatory response. Mol Cell Endocrinol 180(1–2):155–162PubMedCrossRef

10.

Dignass AU, Jung S, Harder-d’Heureuse J, Wiedenmann B (2002) Functional relevance of activin A in the intestinal epithelium. Scand J Gastroenterol 37(8):936–943PubMedCrossRef

11.

Hubner G, Brauchle M, Gregor M, Werner S (1997) Activin A: a novel player and inflammatory marker in inflammatory bowel disease? Lab Invest 77(4):311–318PubMed

12.

Yu EW, Dolter KE, Shao LE, Yu J (1998) Suppression of IL-6 biological activities by activin A and implications for inflammatory arthropathies. Clin Exp Immunol 112(1):126–132PubMedCrossRef

13.

Ota F, Maeshima A, Yamashita S, Ikeuchi H, Kaneko Y, Kuroiwa T et al (2003) Activin A induces cell proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Rheum 48(9):2442–2449PubMedCrossRef

14.

Abe M, Shintani Y, Eto Y, Harada K, Fujinaka Y, Kosaka M et al (2001) Interleukin-1 beta enhances and interferon-gamma suppresses activin A actions by reciprocally regulating activin A and follistatin secretion from bone marrow stromal fibroblasts. Clin Exp Immunol 126(1):64–68PubMedCrossRef

15.

Yu J, Shao LE, Frigon NL Jr, Lofgren J, Schwall R (1996) Induced expression of the new cytokine, activin A, in human monocytes: inhibition by glucocorticoids and retinoic acid. Immunology 88(3):368–374PubMedCrossRef

16.

Ogawa K, Funaba M, Mathews LS, Mizutani T (2000) Activin A stimulates type IV collagenase (matrix metalloproteinase-2) production in mouse peritoneal macrophages. J Immunol 165(6):2997–3003PubMed

17.

Yu J, Dolter KE (1997) Production of activin A and its roles in inflammation and hematopoiesis. Cytokines Cell Mol Ther 3(3):169–177PubMed

18.

Breit S, Ashman K, Wilting J, Rossler J, Hatzi E, Fotsis T et al (2000) The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as activin A. Cancer Res 60(16):4596–4601PubMed

19.

Eto Y, Tsuji T, Takezawa M, Takano S, Yokogawa Y, Shibai H (1987) Purification and characterization of erythroid differentiation factor (EDF) isolated from human leukemia cell line THP-1. Biochem Biophys Res Commun 142(3):1095–1103PubMedCrossRef

20.

Yu J, Shao LE, Lemas V, Yu AL, Vaughan J, Rivier J et al (1987) Importance of FSH-releasing protein and inhibin in erythrodifferentiation. Nature 330(6150):765–767PubMedCrossRef

21.

Hermansson M, Sawaji Y, Bolton M, Alexander S, Wallace A, Begum S et al (2004) Proteomic analysis of articular cartilage shows increased Type II collagen synthesis in osteoarthritis and expression of inhibin {beta}A (activin A), a regulatory molecule for chondrocytes. J Biol Chem 279(42):43514–43521PubMedCrossRef

22.

Tardif G, Hum D, Pelletier JP, Boileau C, Ranger P, Martel-Pelletier J (2004) Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts. Arthritis Rheum 50(8):2521–2530PubMedCrossRef

23.

Kawabata D, Tanaka M, Fujii T, Umehara H, Fujita Y, Yoshifuji H et al (2004) Ameliorative effects of follistatin-related protein/TSC-36/FSTL1 on joint inflammation in a mouse model of arthritis. Arthritis Rheum 50(2):660–668PubMedCrossRef

24.

Cunnane G, Fitzgerald O, Beeton C (2001) Early jont erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinase 1 in rheumatoid arthritis. Arthritis Rheum 44:2263–2274PubMedCrossRef

25.

Ribbens C, Andre B, Jaspar JM (2000) Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol 27:888–893PubMed

26.

Tchetverikov I, Lard LR, Verzijl N (2003) metalloproteinase-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis (abstract). Trans Orthop Res Soc 28:15

27.

Cowell S, Knauper V, Stewart ML, D’Ortho MP, Stanton H, Hembry RM et al (1998) Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3. Biochem J 331(Pt 2):453–458PubMed

28.

Jones EA, English A, Henshaw K, Kinsey SE, Markham AF, Emery P et al (2004) Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis. Arthritis Rheum 50(3):817–827PubMedCrossRef

29.

Vincenti MP, Brinckerhoff CE (2001) Early response genes induced in chondrocytes stimulated with the inflammatory cytokine interleukin-1beta. Arthritis Res 3(6):381–388PubMedCrossRef

30.

Phillips DJ, de Kretser DM (1998) Follistatin: a multifunctional regulatory protein. Front Neuroendocrinol 19(4):287–322PubMedCrossRef

31.

Sakai R, Miwa K, Eto Y (1999) Local administration of activin promotes fracture healing in the rat fibula fracture model. Bone 25(2):191–196PubMedCrossRef

32.

Maeshima A, Zhang YQ, Nojima Y, Naruse T, Kojima I (2001) Involvement of the activin–follistatin system in tubular regeneration after renal ischemia in rats. J Am Soc Nephrol 12(8):1685–1695PubMed

33.

Wankell M, Werner S, Alzheimer C (2003) The roles of activin in cytoprotection and tissue repair. Ann NY Acad Sci 995:48–58PubMedCrossRef

34.

Matrisian LM, Ganser GL, Kerr LD, Pelton RW, Wood LD (1992) Negative regulation of gene expression by TGF-beta. Mol Reprod Dev 32(2):111–120PubMedCrossRef

35.

Heller RA, Schena M, Chai A, Shalon D, Bedilion T, Gilmore J et al (1997) Discovery and analysis of inflammatory disease-related genes using cDNA microarrays. Proc Natl Acad Sci USA 94(6):2150–2155PubMedCrossRef

36.

Behera AK, Thorpe CM, Kidder JM, Smith W, Hildebrand E, Hu LT (2004) Borrelia burgdorferi-induced expression of matrix metalloproteinases from human chondrocytes requires mitogen-activated protein kinase and Janus kinase/signal transducer and activator of transcription signaling pathways. Infect Immun 72(5):2864–2871PubMedCrossRef

37.

Shingu M, Miyauchi S, Nagai Y, Yasutake C, Horie K (1995) The role of IL-4 and IL-6 in IL-1-dependent cartilage matrix degradation. Br J Rheumatol 34(2):101–106PubMedCrossRef

38.

Ohguchi M, Yamato K, Ishihara Y, Koide M, Ueda N, Okahashi N et al (1998) Activin A regulates the production of mature interleukin-1beta and interleukin-1 receptor antagonist in human monocytic cells. J Interferon Cytokine Res 18(7):491–498PubMedCrossRef

39.

Hedger MP, Phillips DJ, de Kretser DM (2000) Divergent cell-specific effects of activin-A on thymocyte proliferation stimulated by phytohemagglutinin, and interleukin 1beta or interleukin 6 in vitro. Cytokine 12(6):595–602PubMedCrossRef

40.

Gebauer M, Saas J, Sohler F, Haag J, Soder S, Pieper M, Bartnik E, Beninga J, Zimmer R, Aigner T (2005) Comparison of the chondrosarcoma cell line SW1353 with primary human adult articular chondrocytes with regard to their gene expression profile and reactivity to IL-1β. Osteoarthritis Cartilage 13:697–708PubMedCrossRef

41.

Jones KL, Brauman JN, Groome NP, de Kretser DM, Phillips DJ (2000) Activin A release into the circulation is an early event in systemic inflammation and precedes the release of follistatin. Endocrinology 141(5):1905–1908PubMedCrossRef

Titel: Activin A suppresses interleukin-1-induced matrix metalloproteinase 3 secretion in human chondrosarcoma cells
verfasst von: Deh-Ming Chang
Shao-Hsiang Liu
Herng-Sheng Lee
Jenn-Hung Lai
Chen-Hung Chen
Publikationsdatum: 01.09.2007
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 11/2007
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-007-0350-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Activin A suppresses interleukin-1-induced matrix metalloproteinase 3 secretion in human chondrosarcoma cells

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2007

The classification of fibromyalgia syndrome

Fibromyalgia: a rheumatologic diagnosis?

Editorial

5-HT3 receptor antagonists regulate autonomic cardiac dysfunction in primary fibromyalgia syndrome

Seronegative Lyme arthritis

Transcription regulatory polymorphism −43T>C in the 5′-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Update Innere Medizin